Xeris Biopharma Holdings (XERS) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $621000.0.
- Xeris Biopharma Holdings' Income towards Parent Company rose 10394.59% to $621000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 7521.91%. This contributed to the annual value of -$54.8 million for FY2024, which is 1191.71% up from last year.
- As of Q3 2025, Xeris Biopharma Holdings' Income towards Parent Company stood at $621000.0, which was up 10394.59% from -$1.9 million recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' Income towards Parent Company registered a high of $621000.0 during Q3 2025, and its lowest value of -$50.8 million during Q4 2021.
- For the 5-year period, Xeris Biopharma Holdings' Income towards Parent Company averaged around -$18.2 million, with its median value being -$16.8 million (2023).
- Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 13237.41% in 2021, then surged by 10394.59% in 2025.
- Quarter analysis of 5 years shows Xeris Biopharma Holdings' Income towards Parent Company stood at -$50.8 million in 2021, then soared by 74.54% to -$12.9 million in 2022, then dropped by 3.56% to -$13.4 million in 2023, then skyrocketed by 61.81% to -$5.1 million in 2024, then skyrocketed by 112.15% to $621000.0 in 2025.
- Its Income towards Parent Company was $621000.0 in Q3 2025, compared to -$1.9 million in Q2 2025 and -$9.2 million in Q1 2025.